Plasma total antioxidant status and cognitive impairments in schizophrenia

[1]  Consuelo Borras,et al.  Females live longer than males: role of oxidative stress. , 2011, Current pharmaceutical design.

[2]  P. Moberg,et al.  Neuropsychological performance in older patients with schizophrenia: a meta-analysis of cross-sectional and longitudinal studies. , 2011, Schizophrenia bulletin.

[3]  Jeffrey K. Yao,et al.  Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. , 2011, Antioxidants & redox signaling.

[4]  M. Keshavan,et al.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. , 2011, Antioxidants & redox signaling.

[5]  D. Goff,et al.  The treatment of cognitive impairment in schizophrenia , 2011, Pharmacology Biochemistry and Behavior.

[6]  T. Kosten,et al.  Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[7]  T. Woo,et al.  Oxidative stress in schizophrenia: An integrated approach , 2011, Neuroscience & Biobehavioral Reviews.

[8]  M. Valko,et al.  Metals, oxidative stress and neurodegenerative disorders , 2010, Molecular and Cellular Biochemistry.

[9]  G. Venkatasubramanian,et al.  Oxidative stress and neopterin abnormalities in schizophrenia: a longitudinal study. , 2010, Journal of psychiatric research.

[10]  M. Baudry,et al.  Prevention of cognitive deficits and brain oxidative stress with superoxide dismutase/catalase mimetics in aged mice , 2010, Neurobiology of Aging.

[11]  Ö. Erel,et al.  Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile , 2009, Psychiatry and clinical neurosciences.

[12]  H. Herken,et al.  A Defect in the Antioxidant Defense System in Schizophrenia , 2009, Neuropsychobiology.

[13]  Philip D. Harvey.  When does cognitive decline occur in the period prior to the first episode of schizophrenia? , 2009, Psychiatry (Edgmont (Pa. : Township)).

[14]  Benoit H. Mulsant,et al.  Nature and course of cognitive function in late-life schizophrenia: A systematic review , 2008, Schizophrenia Research.

[15]  M. Corbetta,et al.  The Reorienting System of the Human Brain: From Environment to Theory of Mind , 2008, Neuron.

[16]  S. Selek,et al.  Oxidative imbalance in obsessive compulsive disorder patients: A total evaluation of oxidant–antioxidant status , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[17]  R. Keefe.  Should cognitive impairment be included in the diagnostic criteria for schizophrenia? , 2008, World psychiatry : official journal of the World Psychiatric Association.

[18]  H. Naito,et al.  Effects of exercise on brain function: role of free radicals. , 2007, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.

[19]  A. Harris,et al.  RBANS neuropsychological profiles within schizophrenia samples recruited from non-clinical settings , 2007, Schizophrenia Research.

[20]  Bruce N. Ames,et al.  Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage , 2006, Proceedings of the National Academy of Sciences.

[21]  N. Kolosova,et al.  Long-term antioxidant supplementation attenuates oxidative stress markers and cognitive deficits in senescent-accelerated OXYS rats , 2006, Neurobiology of Aging.

[22]  M. Atmaca,et al.  Total antioxidant response in patients with schizophrenia , 2006, Psychiatry and clinical neurosciences.

[23]  Víctor Manuel Mendoza-Núñez,et al.  Relationship between oxidative stress and cognitive impairment in the elderly of rural vs. urban communities. , 2006, Life sciences.

[24]  Yan Shen,et al.  Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics , 2006, Schizophrenia Research.

[25]  Michael F. Green,et al.  Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS , 2004, Schizophrenia Research.

[26]  Robert H. Yolken,et al.  Cognitive functioning in schizophrenia and bipolar disorder: comparison of performance on the Repeatable Battery for the Assessment of Neuropsychological Status , 2004, Psychiatry Research.

[27]  Michael F. Green,et al.  Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. , 2004, The Journal of clinical psychiatry.

[28]  Tyrone D. Cannon,et al.  A prospective study of childhood neurocognitive functioning in schizophrenic patients and their siblings. , 2003, The American journal of psychiatry.

[29]  Matcheri Keshavan,et al.  Reduced plasma antioxidants in first-episode patients with schizophrenia , 2003, Schizophrenia Research.

[30]  Richard F. Thompson,et al.  Reversal of age-related learning deficits and brain oxidative stress in mice with superoxide dismutase/catalase mimetics , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Mahadik,et al.  Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. , 2003, The Psychiatric clinics of North America.

[32]  X. Zhang,et al.  Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms , 2003, Psychiatry Research.

[33]  T. Nabeshima,et al.  Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  D. Horrobin,et al.  Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients , 2003, Biological Psychiatry.

[35]  V. Parikh,et al.  Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics , 2002, Schizophrenia Research.

[36]  L. Dixon,et al.  Cognitive correlates of job tenure among patients with severe mental illness. , 2002, The American journal of psychiatry.

[37]  Ömer Akyol,et al.  The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients The possible role of oxidant/antioxidant imbalance , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[38]  X. Zhang,et al.  A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. , 2001, The Journal of clinical psychiatry.

[39]  S. Faraone,et al.  Intelligence quotient and neuropsychological profiles in patients with schizophrenia and in normal volunteers , 2001, Biological Psychiatry.

[40]  M. Altamirano-Lozano,et al.  Total antioxidant levels, gender, and age as risk factors for DNA damage in lymphocytes of the elderly , 2001, Mechanisms of Ageing and Development.

[41]  K. Fukui,et al.  Impairment of Learning and Memory in Rats Caused by Oxidative Stress and Aging, and Changes in Antioxidative Defense Systems , 2001, Annals of the New York Academy of Sciences.

[42]  X. Zhang,et al.  The Effect of Extract of Ginkgo Biloba Added to Haloperidol on Superoxide Dismutase in Inpatients With Chronic Schizophrenia , 2001, Journal of clinical psychopharmacology.

[43]  Jeffrey K. Yao,et al.  Abnormal age-related changes of plasma antioxidant proteins in schizophrenia , 2000, Psychiatry Research.

[44]  David A Lewis,et al.  Catching Up on Schizophrenia Natural History and Neurobiology , 2000, Neuron.

[45]  K. Davies.  Oxidative Stress, Antioxidant Defenses, and Damage Removal, Repair, and Replacement Systems , 2000, IUBMB life.

[46]  M. Altamirano-Lozano,et al.  DNA damage in lymphocytes of elderly patients in relation with total antioxidant levels , 1999, Mechanisms of Ageing and Development.

[47]  Konstantine K. Zakzanis,et al.  Neurocognitive Deficit in Schizophrenia: A Quantitative Review of the Evidence , 1998 .

[48]  Jeffrey K. Yao,et al.  Reduced status of plasma total antioxidant capacity in schizophrenia , 1998, Schizophrenia Research.

[49]  C. Randolph,et al.  The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. , 1998, Journal of clinical and experimental neuropsychology.

[50]  S. Mukherjee,et al.  Elevated Plasma Lipid Peroxides at the Onset of Nonaffective Psychosis , 1998, Biological Psychiatry.

[51]  R. Reddy,et al.  Free radical pathology in schizophrenia: a review. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.

[52]  J J Strain,et al.  The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. , 1996, Analytical biochemistry.

[53]  S. Mukherjee,et al.  Free radical pathology and antioxidant defense in schizophrenia: a review , 1996, Schizophrenia Research.

[54]  R. McCreadie,et al.  The Nithsdale Schizophrenia Surveys. XIV: Plasma Lipid Peroxide and Serum Vitamin E Levels in Patients with and Without Tardive Dyskinesia, and in Normal Subjects , 1995, British Journal of Psychiatry.

[55]  V. Pearson.  Population Policy and Eugenics in China , 1995, British Journal of Psychiatry.

[56]  C. Rice-Evans,et al.  A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. , 1993, Clinical science.

[57]  J. Lohr.  Oxygen radicals and neuropsychiatric illness. Some speculations. , 1991, Archives of general psychiatry.

[58]  D. Jeste,et al.  Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia , 1990, Biological Psychiatry.

[59]  R. Condray,et al.  Cognition, dopamine and bioactive lipids in schizophrenia. , 2011, Frontiers in bioscience.

[60]  M. Deanna.  Pharmacological Strategies for Enhancing Cognition in Schizophrenia , 2010 .

[61]  C. Galletly.  Recent advances in treating cognitive impairment in schizophrenia , 2008, Psychopharmacology.

[62]  D. Best,et al.  Natural history of substance-related problems , 2007 .

[63]  J. Lohr,et al.  Oxidative Mechanisms and Tardive Dyskinesia , 2003, CNS drugs.

[64]  D. Horrobin,et al.  A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. , 2002, Journal of psychiatric research.

[65]  Jeffrey K. Yao,et al.  Oxidative Damage and Schizophrenia , 2001, CNS drugs.

[66]  D. Jeste,et al.  Stability and course of neuropsychological deficits in schizophrenia. , 2001, Archives of general psychiatry.

[67]  H. Herken,et al.  Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia , 2001, Molecular Psychiatry.

[68]  W R Markesbery,et al.  Oxidative stress hypothesis in Alzheimer's disease. , 1997, Free radical biology & medicine.

[69]  P. Laippala,et al.  Age-related changes in the peroxyl radical scavenging capacity of human plasma. , 1997, Free radical biology & medicine.

[70]  S. Mahadik,et al.  ANTIOXIDANTS IN THE TREATMENT OF SCHIZOPHRENIA , 1996 .

[71]  Brown Ja,et al.  Free radical involvement in neuropsychiatric illnesses. , 1995 .